Table 1.
Relationship between the FGFR2+ circulating tumor cells (CTCs) and clinicopathologic features in 100 gastric cancer cases
| Number of FGFR2+ cells | P value | ||
|---|---|---|---|
| ≥5 cells/10 mL (n = 50) | <5 cells/10 mL (n = 50) | ||
| Age | |||
| ≤70 | 21 (42.0%) | 31 (62.0%) | .071 |
| >70 | 29 (58.0%) | 19 (38.0%) | |
| Gender | |||
| Female | 20 (40.0%) | 18 (36.0%) | .837 |
| Male | 30 (60.0%) | 32 (64.0%) | |
| Macroscopic type | |||
| Borrmann's type 4 | 0 (0.0%) | 6 (12.0%) | .15 |
| Other types | 50 (100%) | 44 (88.0%) | |
| Microscopic type | |||
| Differentiated | 27 (54.0%) | 27 (54.0%) | 1.00 |
| Undifferentiated | 23 (46.0%) | 23 (46.0%) | |
| Depth pf invasion | |||
| T1/ T2 | 26 (52.0%) | 31 (62.0%) | .419 |
| T3/ T4 | 24 (24.0%) | 19 (38.0%) | |
| Lymph node metastasis | |||
| N0 | 37 (74.0%) | 37 (74.0%) | 1.00 |
| N1/ N2/ N3 | 13 (26.0%) | 13 (26.0%) | |
| Lymphatic invasion | |||
| Negative | 27 (54.0%) | 31 (62.0%) | .544 |
| Positive | 23 (46.0%) | 19 (38.0%) | |
| Venous invasion | |||
| Negative | 32 (64.0%) | 37 (74.0%) | .387 |
| Positive | 18 (36.0%) | 13 (26.0%) | |
| Tumor size [median] | 25.7 [2.0‐40.0] | 20.0 [1.0‐33.5] | .525 |
| Stage | |||
| I and II | 36 (72.0%) | 36 (72.0%) | 1.000 |
| III and IV | 14 (28.0%) | 14 (28.0%) | |
| CEA [median] | 1.4 [0.5‐3.7] | 1.6 [0.5‐2.6] | .377 |
| CA19‐9 [median] | 1.0 [1.0‐22.0] | 1.0 [1.0‐11.8] | .232 |
Abbreviation: FGFR2+, fibroblast growth factor receptor 2+.